Mylotarg

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Acute Myeloid LeukemiaLeukemiaMyelodysplastic SyndromeAcute Promyelocytic Leukemia

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

1

Vepesid

AAvyxa

Phase 3

502

Astplayer

AAstex Pharmaceuticals, Inc.

Phase 3

33

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

14

Lenograstim

Sanofi

Phase 3

15

Daunorubicin or Idarubicin

Novartis

Phase 3

16

Azacitadine

AbbVie

Phase 3

17

Lodac

Astellas

Phase 3

18

Consolidation Chemotherapy

SShenzhen People's Hospital

Phase 3

19

Grafalon

FFundación Canaria de Investigación Sanitaria

Phase 3

110

Leukine

Sanofi

Preclinical

7Show 18 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Leukemia2 trials

Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant

Completed·Pfizer·Phase 2·NCT00044733·38 enrolled

Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia

Completed·Pfizer·Phase 4·NCT00304447·30 enrolled

Transplantation1 trial

Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00038831·47 enrolled

Relapse1 trial

DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML

Completed·AAcute Leukemia French Association·Phase 1/2·NCT02182596·20 enrolled

Myelodysplastic Syndrome1 trial

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 2/3·NCT00038805·3 enrolled

Hematopoietic Stem Cell Transplant1 trial

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Terminated·VVor Biopharma·Phase 1/2·NCT04849910·67 enrolled

5 more indications

Acute Myeloid Leukemia1 trial

Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment

Completed·GGrupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias·Phase 2·NCT01698879·46 enrolled

Acute Promyelocytic Leukemia1 trial

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Recruiting·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 2·NCT04793919·89 enrolled

CAR1 trial

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Completed·Pfizer··NCT00161668·500 enrolled

MDS1 trial

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

Completed·WWeill Medical College of Cornell University·Phase 2·NCT00195000·43 enrolled

Unspecified1 trial

Vyxeos for Induction of Low- or Intermediate-risk.

Active, not recruiting·SShaare Zedek Medical Center·Phase 2·NCT05599360·20 enrolled

Details

Drug Info

Related News